Cargando…

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials

Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality associated with TNBC. The neoadjuvant setting pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amos, Keith D., Adamo, Barbara, Anders, Carey K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270519/ https://www.ncbi.nlm.nih.gov/pubmed/22461984 http://dx.doi.org/10.1155/2012/385978

Ejemplares similares

Stratifying triple-negative breast cancer: which definition(s) to use?
por: Adamo, Barbara, et al.
Publicado: (2011)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer
por: Mayer, Erica L, et al.
Publicado: (2007)

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2013)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

Clinical Observation of Zhengyuan Capsule Combined with Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer
por: Xiao, Yan, et al.
Publicado: (2022)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
por: Silva, Diogo, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents
por: Garufi, Giovanna, et al.
Publicado: (2022)

Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy
por: Zhang, Wei, et al.
Publicado: (2023)

Triple negative breast cancer: Pitfalls and progress
por: Zagami, Paola, et al.
Publicado: (2022)

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
por: de Pádua Souza, Cristiano, et al.
Publicado: (2023)

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy
por: Jin, Zining, et al.
Publicado: (2015)

Neoadjuvant Chemotherapy Combined with Breast-Conserving Surgery in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni, Antonio, et al.
Publicado: (2016)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Yoon Yang, et al.
Publicado: (2016)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

The Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy and the Epithelial–Mesenchymal Transition
por: Zapperi, Stefano, et al.
Publicado: (2023)

Update on triple-negative breast cancer: prognosis and management strategies
por: Brouckaert, Olivier, et al.
Publicado: (2012)

Update on systemic treatment in early triple negative breast cancer
por: Núñez Abad, Martín, et al.
Publicado: (2021)

Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
por: Bou Zerdan, Maroun, et al.
Publicado: (2022)

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
por: Lehmann, Brian D., et al.
Publicado: (2016)

Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Roy, Sudipta, et al.
Publicado: (2021)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Comment on “Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer”
por: Altundag, Kadri
Publicado: (2017)

ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer
por: Oshi, Masanori, et al.
Publicado: (2020)

Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy
por: Li, Zhijun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f7vrppg7da4tc7ndkc0nk7iei7